Healthcare Services APAC

APAC Ketamine Clinics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Ketamine Clinics Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $788.3 Mn Placeholder estimate
Estimate 2025 $876.6 Mn 22.6% of the global market
Projected 2034 $2.28 Bn 160% Adds $1.40 Bn over 9 forecast years
CAGR 2025–2034 11.2% Faster than 61% of 107 Healthcare Services markets here
Key players 5
  • APAC is 22.64% of the global market.
  • Among regions, the largest is North America at $1.64 Bn.
  • Fastest growing: APAC (this report) at 11.2% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.40 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Ketamine Clinics Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $788.3 Mn — —
2025 (base) $876.6 Mn +$88.3 Mn —
2026 (forecast) $974.8 Mn +$98.2 Mn +11.2%
2027 (forecast) $1.08 Bn +$109.2 Mn +23.7%
2028 (forecast) $1.21 Bn +$121.4 Mn +37.5%
2029 (forecast) $1.34 Bn +$135.0 Mn +52.9%
2030 (forecast) $1.49 Bn +$150.1 Mn +70%
2031 (forecast) $1.66 Bn +$166.9 Mn +89.1%
2032 (forecast) $1.84 Bn +$185.6 Mn +110.2%
2033 (forecast) $2.05 Bn +$206.4 Mn +133.8%
2034 (forecast) $2.28 Bn +$229.5 Mn +160%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Ketamine Clinics Market Analysis at a glance
Market size, 2025$876.6 Mn placeholder estimate
Forecast, 2034$2.28 Bn placeholder estimate
Growth (CAGR), 2025–203411.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, indication and end user (see all)
Key playersJohnson & Johnson, Klarity Health, Mindbloom, Nushama, Novamind (see all)
Active clinical trials10 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Ketamine Clinics Market Analysis Executive Summary

Ketamine clinics give ketamine or esketamine treatments under medical supervision for depression and other mental health conditions.

Key segments of the ketamine Clinics market include treatment (IV Ketamine, Intranasal Esketamine and Ketamine-Assisted Psychotherapy) and indication (Depression, PTSD and Chronic Pain).

Bar chart: Asia Pacific Ketamine Clinics market size, 2024–2034, placeholder estimates. $788.3 Mn in 2024, $876.6 Mn in 2025 and $2.28 Bn in 2034, 11.2% CAGR.
Asia Pacific Ketamine Clinics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Ketamine Clinics Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ketamine Clinics market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the ketamine Clinics market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the ketamine Clinics market.

Competitive Landscape for Ketamine Clinics Market in APAC

The ketamine Clinics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Ketamine Clinics Market in APAC

Ketamine Clinics in APAC: payment and research

How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[1], basic medical insurance (China)⁠[2], the Hospital Authority (Hong Kong)⁠[3], Ayushman Bharat PM-JAY (India)⁠[4], public health insurance (Japan)⁠[5], subsidised public care (Malaysia)⁠[6], Pharmac (New Zealand)⁠[7], PhilHealth (Philippines)⁠[8], MediShield Life (Singapore)⁠[9], the Universal Coverage Scheme (Thailand)⁠[10], JKN (BPJS Kesehatan) (Indonesia)⁠[11], out of pocket and Sehat Sahulat (Pakistan)⁠[12], National Health Insurance (South Korea)⁠[13] and social health insurance (Vietnam)⁠[14]. ClinicalTrials.gov lists 10 studies on Ketamine Clinics that are recruiting, active or about to start in APAC.⁠[15]

[1] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] Hospital Authority. Checked 14 Nov 2026.

[4] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[5] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[6] Ministry of Health Malaysia. Checked 14 Nov 2026.

[7] Pharmac. Checked 14 Nov 2026.

[8] PhilHealth. Checked 14 Nov 2026.

[9] CPF Board, MediShield Life. Checked 14 Nov 2026.

[10] National Health Security Office. Checked 14 Nov 2026.

[11] BPJS Kesehatan. Checked 19 Nov 2026.

[12] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[13] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[14] Vietnam Social Security. Checked 19 Nov 2026.

[15] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Licensing, quality standards and payment models from public and private payers shape how ketamine Clinics services are delivered and paid for in APAC. Government health programs and insurance coverage are key to access.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Ketamine Clinics right now, from free public sources.

Clinical trials

10 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Johnson & Johnson 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Suicide rate, per 100,000 people (WHO)
CountryValueYear
Afghanistan3.32023
Australia13.22023
Bangladesh4.32023
China7.92023
India14.02023
Indonesia1.82023
Japan16.52023
Malaysia4.12023
Myanmar3.82023
Nepal14.02023
New Zealand13.42023
Pakistan7.32023
Philippines2.82023
Singapore7.62023
South Korea27.82023
Thailand10.32023
Vietnam8.82023
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Ketamine Clinics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Ketamine Clinics market in Asia Pacific?
Placeholder estimate: about $876.6 Mn in 2025, rising to about $2.28 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Ketamine Clinics market in Asia Pacific growing?
Placeholder estimate: about 11.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Ketamine Clinics market report cover?
The report splits the market by treatment (IV Ketamine, Intranasal Esketamine, Ketamine-Assisted Psychotherapy), indication (Depression, PTSD, Chronic Pain, Anxiety) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Ketamine Clinics market?
Key players include Johnson & Johnson, Klarity Health, Mindbloom, Nushama and Novamind.
What is driving the Ketamine Clinics market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ketamine Clinics market. Governments and employers are investing more in mental health care.
How many clinical trials on Ketamine Clinics are running in Asia Pacific?
10 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Ketamine Clinics?
PubMed lists 12 papers on Ketamine Clinics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Healthcare Services reports in APAC

See all

Related on mental health

See the topic